PDCD1 and head and neck squamous cell carcinoma: Subgroup analysis based on treatment regimens (anti-PD-1 as monotherapy vs. chemo-immuno combination) revealed that LOX-1+PMN-MDSCs serve as prognostic biomarker in chemo-immunotherapy treated patients, which is the therapy of choice for HNSCC patients.